アジェンスは分析家の予想を上回る 小規模な四半期損失を収めたが,株価は2.15ドルで開店した. Agenus beat analyst expectations with a smaller quarterly loss, but its stock opened at $2.15.

バイオテクノロジー企業 Agenusは 株当たり2.04ドルの四半期損失を報告し,分析者の2.36ドルの損失の予想を上回った. Biotech firm Agenus reported a quarterly loss of $2.04 per share, beating analysts' expectations of a $2.36 loss. 前向きな収益の驚きにかかわらず,同社株は2.15ドルでオープンした. Despite the positive earnings surprise, Agenus stock opened at $2.15. 免疫腫瘍学製品に特化した同社は 市場規模は50.44万ドルで 価格対利益比は -0.19です The company, which specializes in immuno-oncology products, has a market cap of $50.44 million and a price-to-earnings ratio of -0.19. 株価は過去1年間で 2.13ドルから19.69ドルで取引されています. Agenus stock has traded between $2.13 and $19.69 over the past year.